AZD2906, a selective glucocorticoidreceptor (GR) agonist, demonstrates inhibitory concentrations (IC50s) of 2.2 nM in human GR, 0.3 nM in rat peripheral blood mononuclear cells (PBMC), 41.6 nM in human whole blood, and 7.5 nM in rat whole blood, respectively[1]. Additionally, it induces an increase in micronucleated immature erythrocytes within rat bone marrow.
Glucocorticoids receptoragonist 1 (GRA-1) is a highly effective arylpyrazole-based compound that acts as an agonist for the glucocorticoidreceptor. GRA-1 exhibits strong anti-inflammatory properties while maintaining insulin secretion function.
GlucocorticoidReceptorAgonist-4 (Compound Preparation 5) serves as an agonist for glucocorticoidreceptors and can be conjugated with TNF-α antibodies, facilitating research into autoimmune and inflammatory diseases [1].